Targeting CD137 enhances the efficacy of cetuximab

Treatment with cetuximab, an EGFR-targeting IgG1 mAb, results in beneficial, yet limited, clinical improvement for patients with head and neck (HN) cancer as well as colorectal cancer (CRC) patients with WT KRAS tumors. Antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells contributes to...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Kohrt, Holbrook E., Colevas, A. Dimitrios, Houot, Roch, Weiskopf, Kipp, Goldstein, Matthew J., Lund, Peder, Mueller, Antonia, Sagiv-Barfi, Idit, Marabelle, Aurelien, Lira, Ruth, Troutner, Emily, Richards, Lori, Rajapaska, Amanda, Hebb, Jonathan, Chester, Cariad, Waller, Erin, Ostashko, Anton, Weng, Wen-Kai, Chen, Lieping, Czerwinski, Debra, Fu, Yang-Xin, Sunwoo, John, Levy, Ronald
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2014
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4089447/
https://ncbi.nlm.nih.gov/pubmed/24837434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI73014
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi